
Seaweed & Algae · Seaweed extract
Carrageenan
Extract of red seaweeds (Chondrus, Eucheuma and related) · also called Carrageenan gum, E407, E407a (processed Eucheuma seaweed)
Carrageenan is a thickener and gelling agent taken from red seaweeds. It holds together dairy and plant drinks, desserts and processed meats. It is not a nutrient food. Regulators accept it at current use, but the question is not closed: the EU keeps its limit as temporary, and the human studies are tiny. People with ulcerative colitis, and parents choosing infant formula, should ask a doctor.
General information, not medical advice. Last substantive update · Not medically reviewed. A named clinician has not signed off on this page. How this page is made
About Carrageenan
Carrageenan is a thickener from red seaweed, used in many processed foods. It is accepted by regulators at current use, but the EU limit is temporary and the human studies are very small. The strongest worries come from animal work on a broken-down form that is not allowed in food.
What it is
Carrageenan is a sulfated sugar chain taken from red seaweeds. The US regulation describes it as the refined extract of red seaweeds in the families Gigartinaceae and Solieriaceae, with 20 to 40 percent sulfate. It is used in the amount needed as an emulsifier, stabilizer or thickener.
In Europe it is E 407, and processed Eucheuma seaweed, a less refined product, is E 407a. EFSA found it is not absorbed intact. It is not a nutrient food: no nutrition table was read for this page, and the figures that exist are regulators' limits, not advice on how much to eat.
Two things share the name
Poligeenan, also called degraded carrageenan, is a much smaller molecule made on purpose with strong acid and heat. EFSA says it has never been authorised as a food additive and is not used in food. Much of the animal work on gut ulcers and tumours used this form, and for years it was labelled carrageenan.
The two sides disagree on whether food-grade carrageenan can turn into the harmful form in the gut. A 2001 review by Tobacman argued that it can and said use should be reconsidered. A 2019 review and a 2017 addendum by industry-linked authors say it cannot and that many harm claims confuse the two. Neither side's papers prove the question in people.
What the research shows
Regulators: EFSA (2018) found no concern for cancer or genetic damage, and rats showed no harm at the highest doses tested. It still kept the group limit of 75 mg per kg body weight per day as temporary because of gaps in the chemistry, intake data and biology. JECFA lists the limit as not specified.
People: three small studies exist. In 12 people with ulcerative colitis, 3 on carrageenan capsules relapsed and none on placebo did. In 20 healthy men, 2 weeks of capsules did not change insulin sensitivity overall, but overweight men had lower sensitivity and higher CRP and IL-6. A survey of 922 adults using protein drinks saw no overall link with CRP. None of these tested ordinary food.
Additive versus whole seaweed and capsules
Carrageenan is a refined extract, not whole sea moss or Irish moss. The trials used capsules and the survey used protein drinks. No study compared the additive with the whole seaweed, so findings should not be carried across. Sea moss has its own page.
At a glance
Traditional uses history, not proof
- The refined extract is a modern food additive
- Red seaweeds such as Irish moss are eaten as food; no traditional medicine use was verified
Studied for research
- Safety at current food use, accepted by regulators with open questions (EFSA, JECFA, FDA)
- Ulcerative colitis relapse, very low certainty (12 people finished)
- Insulin sensitivity, very low certainty (20 healthy men, 2 weeks)
- Inflammation marker CRP, very low certainty (survey)
- Gut tumours and ulcers, animal and lab evidence only
- Use as a food thickener (technical use, not a health benefit)
Main compounds
- Kappa, iota and lambda carrageenan (sulfated polysaccharides)
- Low-weight carrageenan fraction
- Poligeenan (degraded carrageenan, not a food additive)
Common forms
- Refined carrageenan (E 407)
- Processed Eucheuma seaweed (E 407a)
- Capsules used in two small trials, not a food form
- Whole sea moss and Irish moss are different products and are not covered
Research links: EFSA 2018 re-evaluation of carrageenan (E 407) · 2017 trial: carrageenan and ulcerative colitis relapse · 2024 trial: carrageenan and insulin sensitivity · Research Library · Genes & Biomarkers Library
What it is and its history
- Accepted scientific name
- Carrageenan (E 407): refined extract of red seaweeds
- Naming authority
- Not a single species. The US regulation names Chondrus crispus, Chondrus ocellatus, Eucheuma cottonii, Eucheuma spinosum and several Gigartina species (families Gigartinaceae and Solieriaceae).
- Common names
- Carrageenan (English); Carrageenan gum (English); E407 (English); E407a (processed Eucheuma seaweed) (English); Carragenina (Spanish)
- Family or group
- Gigartinaceae and Solieriaceae, the red seaweed families named in the US regulation. Carrageenan itself is a refined seaweed extract, not a plant part.
- Classification
- Not stated by the sources read > Red algae > Rodophyceae (as written in the regulation) > Not stated > Gigartinaceae and Solieriaceae (per the regulation) > Chondrus, Eucheuma, Gigartina > Several; see accepted_name
- Native range
- Not verified from a source read.
- Habitat
- Not verified from a source read.
- Cultivation
- Not verified from a source read.
- Harvest and processing
- Refined carrageenan is prepared by aqueous extraction from the named red seaweeds (US regulation). Processed Eucheuma seaweed (E 407a) is a less refined seaweed product with more cellulose, and is sometimes bleached (EFSA).
- Look-alikes and adulterants
- Name: Poligeenan (degraded carrageenan); Note: A far smaller molecule made with acid and heat; not a food additive.; Name: Agar, alginate and whole sea moss; Note: Other seaweed gelling agents and the whole seaweed; they have their own pages and are different products.
- Sustainability and conservation
- Not assessed.
Photographs

Traditional use and history history, not clinical proof
| Tradition or era | Documented use | Source |
|---|---|---|
| Regulatory history (EFSA's account) | JECFA set an acceptable daily intake of 0 to 75 mg per kg body weight in 1974. In 1984 it changed to 'not specified', and in 2002 it set a group 'not specified' for carrageenan plus processed Eucheuma seaweed. The EU scientific committee kept 0 to 75 mg per kg in 1978 and 1996. In 1983 IARC rated carrageenan group 3. | EFSA 2018 (full text read); verified |
| Traditional seaweed use | Irish moss (Chondrus crispus) is a traditional food seaweed, but no source read documents its history or any traditional medicine use. Not verified. | NOT verified (no source read) |
Traditional use shows how it was used. It does not show that it works or is safe today.
What is inside, and how it may work
What it contains and how those compounds act in cells and animals. Laboratory and animal mechanisms are not proven effects in people.
Main compounds
| Compound | Family | Where it is concentrated | Activity studied | Level of evidence |
|---|---|---|---|---|
| Carrageenan polysaccharides (kappa, iota, lambda) | sulfated polysaccharide | Red seaweed thallus (extracted) 20 to 40 percent sulfate on a dry-weight basis (US regulation); EU: kappa, iota and lambda forms by number of sulfate groups | Gives thickening and gelling in foods. It is not absorbed intact (EFSA). 10 9 | Regulation |
| Low-weight carrageenan fraction (below 50 kDa) | sulfated polysaccharide fragments | EFSA refers to an existing 5% limit on this fraction in the EU specification; not checked against the current regulation | Associated with potential gut inflammation because it resembles poligeenan (EFSA). 9 | Regulatory |
| Poligeenan | degraded carrageenan | Average molecular weight 10 to 20 kDa (EFSA) | Causes gut inflammation and tumours in animals; not a food additive. 9 6 | Animal research |
Mechanisms, receptors and pathways
| Target or pathway | Gene or receptor | What was found | Level |
|---|---|---|---|
| Inflammation signals in gut and immune cells | Toll-like receptor and BCL10, NF-kB, IL-8 (cell studies, as reported by EFSA) | In cell studies, carrageenan switched on NF-kB and IL-8 through Toll-like receptor and BCL10. EFSA noted that many of these tests did not describe which carrageenan was used. In the 2024 trial, carrageenan raised immune-cell activation in cells from the participants. These are lab findings. 9 7 | Lab |
| Breakdown of food-grade into degraded carrageenan | Not applicable | Tobacman suggests food-grade carrageenan may be broken down by stomach acid or gut bacteria; McKim and colleagues (industry-linked) say it cannot become poligeenan in the body. The question is open in people. 6 4 | Disputed |
Absorption, metabolism and elimination
- Absorption
- Not absorbed intact (EFSA); not degraded or absorbed in the gut in the species studied (Cohen and Ito 2002).
- Metabolism
- Not found.
- Elimination
- Not found in the sources read.
- Bioavailability
- Not established in people.
Isolated compounds versus whole extracts
Carrageenan is a refined extract, not whole seaweed. The animal work on gut damage mostly used the degraded form. The trials used capsules, not food. No study compared the additive with whole sea moss or Irish moss.
Nutritional composition
No nutrition table was read for this page. Carrageenan is an additive used in small amounts, not a nutrient source, and the earlier summary reports no USDA FoodData Central entry. For the whole seaweed, see the sea moss page. Regulators' only quantity is a limit: the EU group acceptable daily intake of 75 mg per kg of body weight per day (temporary), against JECFA's 'not specified'. That is a regulator's safety limit, not advice on how much to eat.
1 high certainty3 very low certainty1 not enough evidence
What was looked at
The 5 benefits and uses checked for Carrageenan, each with how strong the evidence is. Tap one to open it.
- Gut inflammation: ulcerative colitis relapse (a safety question)Very low certainty
- Gut ulcers and tumours in animals (lab and animal evidence only)Not enough evidence
- Insulin sensitivity and blood sugar control (a safety question)Very low certainty
- Inflammation marker CRP (survey of protein-drink users)Very low certainty
- Use in foods as a thickener, gelling agent and stabiliser (technical use, not a health benefit)High certainty
Lab markers tracked in the studies
Interleukin-6 and fecal calprotectin (gut inflammation markers)Insulin sensitivityC-reactive protein (CRP)Gut permeability (leaky gut markers)
What is Carrageenan good for?
What has been studied and how strong the human evidence is. Most of these are safety questions, not benefits. The evidence is small and mostly very low.
Benefits, one by one
Each card is a research question, not a promise. Tap a goal to filter. Open a card to see the studies, doses and limits.
Gut inflammation: ulcerative colitis relapse (a safety question)
Very low certaintyOne very small trial asked whether carrageenan capsules bring on earlier relapse in people with ulcerative colitis in remission. Three of those given carrageenan relapsed and none given placebo did, but only 12 people finished. This is a possible harm, not a benefit.
2 studiesCapsules with less carrageenan than the average daily intake from die…
Studies, doses and limits
What the trials found
One randomised, double-blind trial: 12 people finished. 3 given carrageenan capsules relapsed; none given placebo did (p = 0.046). IL-6 rose in the carrageenan group (p = 0.02); fecal calprotectin rose with p = 0.06.
Results
A signal of possible harm in a tiny trial. It cannot settle the question, and EFSA says it needs further investigation.
Effect sizes as reported
3 relapses of the carrageenan group versus 0 of the placebo group among 12 completers; log-rank p = 0.046.
Why this rating
Very low: 12 completers, one trial, capsules rather than food, and authors who started with a concern about carrageenan.
Form and dose studied
Capsules with less carrageenan than the average daily intake from diet (amount not given in the abstract). Not a food form.
Who was studied
Adults with ulcerative colitis in remission.
Limits
Tiny sample. Capsules, not foods. Not repeated in the sources we read.
Why researchers looked
Carrageenan is in many processed foods, and lab and animal work (mostly with the degraded form) linked it to gut inflammation, so researchers tested it in people with ulcerative colitis.
Traditional use
Carrageenan is made from red seaweeds, which have long been eaten in Ireland and other places. The extract is a modern food additive and has no traditional medicine use we could source.
Proposed mechanism In vitro and regulatory summary
In cell studies carrageenan switched on inflammation signals. EFSA says many of those tests did not describe which kind of carrageenan was used, and that results suggesting it might worsen inflammatory bowel disease in people need clarification.
A proposed mechanism does not show that the effect happens in people.
If you have ulcerative colitis or Crohn's disease, ask your gut doctor; see the Safety tab.
Gut ulcers and tumours in animals (lab and animal evidence only)
Not enough evidenceAnimal studies of the broken-down form (poligeenan) clearly caused gut damage. Whether the food additive does the same is disputed. Regulators judge the food additive acceptable; critics disagree. No human result shows either.
5 studiesMostly degraded carrageenan (poligeenan) or poorly described samples;…
Studies, doses and limits
What the trials found
No human trial of tumours or gut ulcers was found.
Results
Animal and lab only. A critical review (Tobacman 2001) says both forms were linked to ulcers and tumours in animals. A 2002 review (Cohen and Ito) found no credible evidence of cancer or colon tumour promotion for food-grade carrageenan and noted that many studies used doses far above human intake.
Effect sizes as reported
No numbers in the abstracts. EFSA: rats showed no effects at the highest doses tested (3,400 to 3,900 mg per kg body weight per day in a subchronic study; up to 7,500 in chronic studies); monkeys given degraded carrageenan had colon lesions.
Why this rating
Insufficient for people: animal and lab work only, with sides that disagree and industry links on one side.
Form and dose studied
Mostly degraded carrageenan (poligeenan) or poorly described samples; this is not the food additive.
Who was studied
Rats, guinea pigs, pigs, monkeys.
Limits
Animal doses are far above human intake. Many studies did not say which form was tested. Two of the papers cited are linked to a carrageenan maker, and one is by a critic who has argued against carrageenan.
Why researchers looked
Early animal work used a degraded form to cause gut ulcers on purpose, which raised the question of the food additive.
Proposed mechanism Animal research
Tobacman (2001) suggested the damage could come from small-molecule contamination, breakdown in stomach acid, or gut bacteria. Industry-linked reviewers (FMC-linked) say food-grade carrageenan cannot turn into the degraded form in the body. EFSA says the colon findings relate mainly to the degraded form.
A proposed mechanism does not show that the effect happens in people.
See the Safety tab for what EFSA, JECFA and FDA concluded.
Insulin sensitivity and blood sugar control (a safety question)
Very low certaintyA small two-week crossover trial in 20 healthy young men found no overall change in insulin sensitivity from carrageenan capsules. In the overweight men, insulin sensitivity was lower and inflammation markers higher. It is a possible harm signal that needs repeating.
2 studiesCarrageenan capsules, 250 mg twice a day for 2 weeks, in a trial; not…
Studies, doses and limits
What the trials found
Randomised, double-blind, placebo-controlled crossover trial, 20 men, carrageenan 250 mg in the morning and evening for 2 weeks. Overall insulin sensitivity did not differ. In overweight participants insulin sensitivity was lower, CRP and IL-6 were higher and gut permeability was higher (interaction p = 0.01 to 0.04).
Results
No overall effect; a possible harm in overweight men in one small trial.
Effect sizes as reported
Overall: no significant difference. BMI-by-treatment interactions: p = 0.04 (OGTT-based index), p = 0.01 (fasting insulin resistance), p = 0.04 (liver insulin sensitivity index).
Why this rating
Very low: 20 healthy young men, 2 weeks, capsules, and the finding is a subgroup effect.
Form and dose studied
Carrageenan capsules, 250 mg twice a day for 2 weeks, in a trial; not a food form.
Who was studied
Healthy young men.
Limits
Small, short, men only, capsules, subgroup finding.
Why researchers looked
Animal studies suggested carrageenan could make the body less sensitive to insulin and raise gut inflammation.
Proposed mechanism Human trial interpretation
The authors propose pro-inflammatory effects in the gut and raised gut permeability. This is their interpretation of trial and cell results, not a tested mechanism.
A proposed mechanism does not show that the effect happens in people.
People with diabetes or prediabetes: ask your doctor; see the Safety tab.
Inflammation marker CRP (survey of protein-drink users)
Very low certaintyA US survey of 922 adults who use protein drinks found no clear link between carrageenan-containing drinks and the inflammation marker CRP. In people who said their health was poor, the numbers were higher, but this was a subgroup finding.
1 studiesCarrageenan in protein drinks, amount not measured.
Studies, doses and limits
What the trials found
Observational survey (NHANES) of 922 US adults using protein supplement beverages. Overall ratio of CRP 1.07 (95% CI 0.74 to 1.55) for carrageenan-containing liquid drinks against powder drinks; 0.98 (0.66 to 1.47) in the second analysis.
Results
No overall link; a possible link in people in poorer health that the authors call hypothesis-generating.
Effect sizes as reported
Primary ratio 1.07; secondary 0.98; in poorer health 1.91 (0.92 to 3.97) and 3.14 (1.43 to 6.91); interaction p = 0.04.
Why this rating
Very low: a survey that guessed exposure from the type of drink, with a subgroup signal.
Form and dose studied
Carrageenan in protein drinks, amount not measured.
Who was studied
US adults using protein drinks.
Limits
Cannot show cause. Exposure was guessed. One author's spouse works for PepsiCo.
Why researchers looked
Researchers wanted to know whether carrageenan in everyday products goes with higher inflammation in the real world.
Proposed mechanism Not applicable
Not tested in this survey.
A proposed mechanism does not show that the effect happens in people.
None specific.
Use in foods as a thickener, gelling agent and stabiliser (technical use, not a health benefit)
High certaintyCarrageenan is used to hold dairy and plant drinks, desserts and meats together. That is a food-making job, not a health effect.
2 studiesRefined carrageenan (E 407, US 21 CFR 172.620) and processed Eucheuma…
Studies, doses and limits
What the trials found
Not a health trial. FDA's regulation allows it as an emulsifier, stabilizer or thickener in the amount necessary.
Results
A technical use only. We make no health claim.
Why this rating
High that this is what it is used for and how regulators define it (regulation text read). No health benefit is claimed.
Form and dose studied
Refined carrageenan (E 407, US 21 CFR 172.620) and processed Eucheuma seaweed (E 407a).
Limits
Says nothing about health effects.
Why researchers looked
Regulators review it because it is eaten widely in processed foods.
Traditional use
Red seaweeds have been eaten for centuries; the refined extract is a modern industrial ingredient.
Proposed mechanism Regulation
Carrageenan is a sulfated polysaccharide of galactose and anhydrogalactose; FDA text gives 20 to 40 percent sulfate.
A proposed mechanism does not show that the effect happens in people.
See the Safety tab.
Connections to the rest of health
How Carrageenan connects to the rest of our health knowledge graph. Every link says what kind of connection it is. A safety link (for example to the liver) is a warning, not a benefit. A study that merely mentions a topic never creates a benefit link.
Explore every connection: goals, body systems, organs, symptoms, genes
A. Wellness goals
| Connected to | Kind of connection | Evidence status | Context | Studies |
|---|---|---|---|---|
| Gut Health | Very low certainty | Gut inflammation: ulcerative colitis relapse (a safety question): One very small trial asked whether carrageenan capsules bring on earlier relapse in people with ulcerative colitis in remission. Three of those given carrageenan relapsed and none given placebo did, but only 12 people finished. This is a possible harm, not a benefit. | 1 9 | |
| Digestive Support | Very low certainty | Gut inflammation: ulcerative colitis relapse (a safety question): One very small trial asked whether carrageenan capsules bring on earlier relapse in people with ulcerative colitis in remission. Three of those given carrageenan relapsed and none given placebo did, but only 12 people finished. This is a possible harm, not a benefit. | 1 9 | |
| Gut Health | Not enough evidence | Gut ulcers and tumours in animals (lab and animal evidence only): Animal studies of the broken-down form (poligeenan) clearly caused gut damage. Whether the food additive does the same is disputed. Regulators judge the food additive acceptable; critics disagree. No human result shows either. | 6 2 4 8 9 | |
| Digestive Support | Not enough evidence | Gut ulcers and tumours in animals (lab and animal evidence only): Animal studies of the broken-down form (poligeenan) clearly caused gut damage. Whether the food additive does the same is disputed. Regulators judge the food additive acceptable; critics disagree. No human result shows either. | 6 2 4 8 9 | |
| Blood Sugar Balance | Very low certainty | Insulin sensitivity and blood sugar control (a safety question): A small two-week crossover trial in 20 healthy young men found no overall change in insulin sensitivity from carrageenan capsules. In the overweight men, insulin sensitivity was lower and inflammation markers higher. It is a possible harm signal that needs repeating. | 7 9 | |
| Inflammation Balance | Very low certainty | Inflammation marker CRP (survey of protein-drink users): A US survey of 922 adults who use protein drinks found no clear link between carrageenan-containing drinks and the inflammation marker CRP. In people who said their health was poor, the numbers were higher, but this was a subgroup finding. | 3 | |
| Preventive Wellness | High certainty | Use in foods as a thickener, gelling agent and stabiliser (technical use, not a health benefit): Carrageenan is used to hold dairy and plant drinks, desserts and meats together. That is a food-making job, not a health effect. | 10 9 |
B. Body systems
| Connected to | Kind of connection | Evidence status | Context | Studies |
|---|---|---|---|---|
| Digestive System | Biological association | Very low certainty | Studied for: Gut inflammation: ulcerative colitis relapse (a safety question) Studied for: Gut ulcers and tumours in animals (lab and animal evidence only) | 1 9 6 2 4 8 10 |
| Endocrine System | Biological association | Very low certainty | Studied for: Insulin sensitivity and blood sugar control (a safety question) | 7 9 |
| Immune System | Biological association | Very low certainty | Studied for: Inflammation marker CRP (survey of protein-drink users) | 3 |
E. Health conditions
| Connected to | Kind of connection | Evidence status | Context | Studies |
|---|---|---|---|---|
| Ulcerative colitis | Preliminary, very small trial | 3 of 12 finishers given carrageenan capsules relapsed; none on placebo did. 3 of 12 finishers on carrageenan capsules relapsed; none on placebo did. Preparation or compound: Carrageenan capsules |
1 9 | |
| Insulin resistance | Preliminary, small trial | No overall change in 20 healthy young men; lower insulin sensitivity in the overweight ones. No overall change in 20 healthy young men; lower sensitivity in overweight men. Preparation or compound: Carrageenan capsules |
7 | |
| Food allergy | Adverse effect or risk | One case report | One anaphylaxis case during a barium enema; EFSA found no case reports from eating foods with carrageenan. One anaphylaxis case during a barium enema; none found from eating foods with carrageenan. Preparation or compound: Carrageenan as an additive |
5 9 |
I. Biomarkers
| Connected to | Kind of connection | Evidence status | Context | Studies |
|---|---|---|---|---|
| Interleukin-6 and fecal calprotectin (gut inflammation markers) | Biological association | Very low certainty | Measured in trials: raised in the carrageenan group (IL-6); calprotectin trend. A lab change is not the same as a health benefit. | 1 |
| Insulin sensitivity | Biological association | Very low certainty | Measured in trials: no overall change; lower in overweight participants. A lab change is not the same as a health benefit. | 7 |
| C-reactive protein (CRP) | Biological association | Very low certainty | Measured in trials: mixed: higher in overweight men in a trial; no overall link in a survey. A lab change is not the same as a health benefit. | 7 3 |
| Gut permeability (leaky gut markers) | Biological association | Very low certainty | Measured in trials: higher in the carrageenan period. A lab change is not the same as a health benefit. | 7 |
K. Biological pathways
| Connected to | Kind of connection | Evidence status | Context | Studies |
|---|---|---|---|---|
| NF-kB inflammation signalling | Preliminary mechanism | Lab | Switched on by carrageenan in cell studies (lab only). | 9 |
| Ulcerative colitis | Preliminary mechanism | Human | One tiny trial saw earlier relapse; EFSA says it needs further investigation. | 1 9 |
| Insulin resistance | Preliminary mechanism | Human | A small crossover trial saw a signal in overweight men. | 7 |
L. Active compounds
| Connected to | Kind of connection | Evidence status | Context | Studies |
|---|---|---|---|---|
| Carrageenan polysaccharides (kappa, iota, lambda) | Biological association | Regulation | Gives thickening and gelling in foods. It is not absorbed intact (EFSA). Preparation or compound: Red seaweed thallus (extracted) |
10 9 |
| Low-weight carrageenan fraction (below 50 kDa) | Biological association | Regulatory | Associated with potential gut inflammation because it resembles poligeenan (EFSA). | 9 |
| Poligeenan | Biological association | Animal | Causes gut inflammation and tumours in animals; not a food additive. | 9 6 |
Each connection is stored with the ingredient, the connected record, the kind of connection, the evidence status, the supporting studies, the preparation or compound involved, and a review date (last reviewed October 26, 2026).
Evidence at a glance: what the research found for 5 outcomes
Each outcome below is one thing researchers measured. Certainty is how far the evidence can be trusted, not how well it works. The full studies are on the next tab.
The evidence
The research centre for Carrageenan. Every record here was checked against PubMed or the publisher's page; we never list a study we have not verified.
Evidence by outcome
Bars show how many studies we found for each outcome, not how well it works. People are added up across trials only (reviews are not added, to avoid double counting).
How we rate evidence
High certainty
Several well-run trials or reviews agree; further research is unlikely to change the picture much.
Moderate certainty
Good trials point the same way, but some doubt remains.
Low certainty
Small, short or inconsistent trials. The finding could change with better research.
Very low certainty
Very little or very weak human data. Treat as a possibility only.
Mixed findings
Trials or reviews disagree with each other.
Not enough evidence
Not enough human research to say either way.
Evidence against
Good research found no benefit, or found harm.
We take the reviewers' own risk-of-bias and GRADE statements where they exist, and otherwise judge from study size, design, consistency, directness and whether a product matches what is sold. Many publications do not make evidence high. Method note: We started from our existing carrageenan summary, read the EFSA 2018 opinion, the JECFA database page and the US regulation text, and re-read PubMed abstracts for the trials, reviews and a case report. Only abstracts were read for studies. Items we could not verify are flagged in the research gaps.
Study library: every study we checked 11
| Study | Design | People | Product, dose, length | Result |
|---|---|---|---|---|
| Bhattacharyya 2017 A randomized trial of the effects of the no-carrageenan diet on ulcerative colitis disease activity. Nutr Healthy Aging · PMID 28447072 · DOI |
Randomised controlled trial |
Adults with ulcerative colitis in remission; 12 completed the study questionnaires | Carrageenan-containing capsules versus placebo capsules (carrageenan in the capsules was less than the average daily intake from diet) Capsules Up to 1 year, or until relapse · vs Placebo capsules; all took part in a no-carrageenan diet |
3 people given carrageenan capsules relapsed and none given placebo did (log-rank p = 0.046). Interleukin-6 rose in the carrageenan group (p = 0.02) and fecal calprotectin rose (p = 0.06, not significant) between start and end, not in the placebo group. 3 relapses with carrageenan versus 0 with placebo; IL-6 p = 0.02; fecal calprotectin p = 0.06 (Not given in the abstract) Methods, limits and fundingOutcomes: Relapse (rise of 2 or more points on the SCCAI and stronger treatment), blood markers Limitations: Only 12 people completed it, so one or two people can change the result. Capsules, not food. The senior author (Tobacman) is also the author of the 2001 review that argued against carrageenan, so the authors started with a view. Funding is not stated in the abstract. Funding and conflicts: Funding is not stated in the abstract. Read: abstract |
| Cohen 2002 A critical review of the toxicological effects of carrageenan and processed eucheuma seaweed on the gastrointestinal tract. Crit Rev Toxicol · PMID 12389870 · DOI |
Narrative review animal studies animal |
Animal toxicology studies of food-grade carrageenan and processed Eucheuma seaweed | Food-grade carrageenan and processed Eucheuma seaweed |
The authors found food-grade carrageenan is not broken down or absorbed in the gut of the species studied, found no credible evidence of cancer or tumour promotion in the colon of rodents, and noted that many studies used doses far above human intake. Poligeenan is not a food additive. No numbers in the abstract (Not applicable) Methods, limits and fundingOutcomes: Gut effects, absorption, cancer in animals Limitations: A 2002 review of animal studies; it reflects the data then. Funding is not stated in the abstract. Funding and conflicts: Funding is not stated in the abstract. Read: abstract |
| Lam 2026 Evaluation of the Association Between Carrageenan and Systemic Inflammation: Results From the National Health and Nutrition Examination Survey. Mol Nutr Food Res · PMID 42117307 · DOI |
Cross sectional survey |
922 922 US adults who used protein supplement beverages and had a CRP blood test (NHANES 1999-2010 and 2015-2023) |
Carrageenan-containing liquid protein beverages (liquid products used as a stand-in for exposure) versus beverages made from powders Protein supplement beverages · vs Powder-prepared beverage users; second analysis with versus without carrageenan (n = 622) |
Overall, carrageenan-containing protein beverages were not significantly linked to CRP. In people who reported poorer health, ratios were higher (primary 1.91, 95% CI 0.92 to 3.97; secondary 3.14, 95% CI 1.43 to 6.91). The authors call this hypothesis-generating. Primary ratio 1.07; secondary 0.98 (not significant); interaction with health status p = 0.04 (Primary 0.74 to 1.55; secondary 0.66 to 1.47) Methods, limits and fundingOutcomes: CRP (a blood marker of inflammation) Limitations: A survey, so it cannot show cause. Exposure was guessed from the type of protein drink, not measured. Subgroup finding only. Funding and conflicts: Conflict statement: one author's spouse is employed by PepsiCo. No other conflicts stated for this work. Read: abstract |
| McKim 2019 Clarifying the confusion between poligeenan, degraded carrageenan, and carrageenan: A review of the chemistry, nomenclature, and in vivo toxicology by the oral route. Crit Rev Food Sci Nutr · PMID 29902080 · DOI |
Narrative review chemistry toxicology animal |
Chemistry and animal oral toxicology of carrageenan, degraded carrageenan and poligeenan | Carrageenan, degraded carrageenan, poligeenan |
The authors argue that carrageenan cannot be turned into poligeenan inside the body and that older studies often used the word carrageenan for the degraded form, so concerns about the additive are unfounded. No numbers in the abstract (Not applicable) Methods, limits and fundingOutcomes: Chemistry, naming, toxicology Limitations: Written by consultants; the carrageenan maker FMC Corporation is named in the follow-up addendum (Weiner 2017), and the funder of this paper is not stated in the abstract. Treat as industry-linked. A review, not a trial. Funding and conflicts: Funding is not stated in this abstract. The related addendum carries an FMC Corporation copyright line, and the authors are consultants (IONTOX, TOXpertise, Celtic Colloids). Flagged as industry-linked. Read: abstract |
| Tarlo 1995 Anaphylaxis to carrageenan: a pseudo-latex allergy. J Allergy Clin Immunol · PMID 7751512 · DOI |
Case report |
1 One patient who had anaphylaxis during a barium enema |
Carrageenan as a component of the barium enema solution |
Carrageenan, a component of the barium enema solution, gave positive allergy skin test and IgE blood test results. The patient's stomach and bowel symptoms went away on a carrageenan-free diet. The authors called carrageenan a previously unreported cause of anaphylaxis during barium enema and suggested it could account for some symptoms from milk products or baby formula. One patient (Not applicable) Methods, limits and fundingOutcomes: Skin test and IgE blood test reactions to carrageenan Limitations: A single 1995 case report. It shows allergy can happen but gives no rate. EFSA (2018) found no case reports of significant allergic reactions after eating foods that contain carrageenan. Funding and conflicts: Funding is not stated in the abstract. Read: abstract |
| Tobacman 2001 Review of harmful gastrointestinal effects of carrageenan in animal experiments. Environ Health Perspect · PMID 11675262 · DOI |
Narrative review animal studies animal |
Animal studies of carrageenan, degraded carrageenan and the gut | Undegraded and degraded carrageenan |
The author concluded that both undegraded and degraded carrageenan were linked to intestinal ulcers and tumours in animals, and that widespread use in the Western diet should be reconsidered. She suggested this could be from small-molecule contamination, breakdown by stomach acid, or gut bacteria. No numbers in the abstract (Not applicable) Methods, limits and fundingOutcomes: Gut ulcers and tumours in animals Limitations: A 2001 narrative review of animal work, by one author; not a trial in people. Regulators and industry-funded reviews dispute that food-grade carrageenan breaks down into the harmful form in the body. Funding is not stated in the abstract. Funding and conflicts: Funding is not stated in the abstract. Read: abstract |
| Wagner 2024 Carrageenan and insulin resistance in humans: a randomised double-blind cross-over trial. BMC Med · PMID 39593091 · DOI |
Randomised crossover trial |
20 20 healthy young men (average age 27.4 years, average BMI 24.5) |
Carrageenan capsules versus placebo Capsules 250 mg in the morning and 250 mg in the evening 2 weeks per treatment · vs Placebo (crossover) |
Overall insulin sensitivity did not differ between carrageenan and placebo. There were differences by body weight: in overweight participants, carrageenan went with lower whole-body and liver insulin sensitivity, higher CRP and IL-6, a trend to more brain inflammation on MRI, and higher gut permeability. In cells from the participants' blood, carrageenan raised immune-cell activation in the lab. Overall: no significant difference. BMI-by-treatment interaction p = 0.04 (insulin sensitivity index), p = 0.01 (fasting insulin resistance), p = 0.04 (liver insulin sensitivity index) (Not given in the abstract) Methods, limits and fundingOutcomes: Insulin sensitivity (oral glucose test and clamp), CRP, IL-6, gut permeability, brain MRI, gut bacteria Limitations: Only 20 men, 2 weeks, capsules. The overweight finding is a subgroup effect (an interaction) in a small trial, so it needs repeating. The authors' own conclusion is worded as 'may contribute'. Trial registration NCT02629705. Funding and conflicts: Competing interests listed for some authors are lecture fees and advisory roles with drug companies (NovoNordisk, Eli Lilly, Sanofi and others), described as outside this work. No carrageenan industry funding is stated in the abstract. Read: abstract |
| Weiner 2017 Addendum to Weiner, M.L. (2016) Parameters and Pitfalls to Consider in the Conduct of Food Additive Research, Carrageenan as a Case Study. Food Chem Toxicol · PMID 28651808 · DOI |
Commentary n/a |
Two recent publications that the authors say mislabel degraded carrageenan as carrageenan | Not applicable |
The authors say many papers use the name carrageenan for degraded carrageenan or poligeenan, which are not food additives and have very different properties, and call for rigorous peer review. No numbers in the abstract (Not applicable) Methods, limits and fundingOutcomes: Sample identity and study quality in carrageenan research Limitations: A commentary, not a trial. Copyright line: FMC Corporation, a carrageenan maker. Funding and conflicts: Industry-linked: copyright FMC Corporation (a carrageenan maker). Read: abstract |
| s-efsa-2018 EFSA ANS Panel (2018). Re-evaluation of carrageenan (E 407) and processed Eucheuma seaweed (E 407a) as food additives. EFSA Journal 16(4):5238 · Source |
Regulatory opinion n/a |
Methods, limits and fundingRead: full-text | ||
| s-fda-21cfr172-620 US eCFR, 21 CFR 172.620 Carrageenan · Source |
Regulation n/a |
Methods, limits and fundingRead: full-text | ||
| s-jecfa-carrageenan WHO JECFA database: Carrageenan (INS 407) · Source |
Regulatory database n/a |
Methods, limits and fundingRead: full-text |
What we do not know yet
- No trial of carrageenan eaten as ordinary food was found for colitis, insulin or any other outcome.
- Only three small human studies were read: a 12-person colitis trial, a 20-man insulin trial and a survey.
- Whether food-grade carrageenan can break down into the harmful form in the body is argued by both sides and is not settled in people.
- Liver safety, medicine interactions, pregnancy in people, heavy metals and iodine in the source seaweeds were not researched.
- The 2016 US organic board vote was not rechecked and is not stated.
How new research is added
New studies are found by a saved PubMed search and placed in a review queue before the page changes.
Lab markers
What changed in blood or saliva tests during trials. A changed number is not the same as feeling or being healthier, and we give no "normal ranges".
Inflammatory 1
C-reactive protein (CRP)
Mixed: higher in overweight men in a trial; no overall link in a survey in trials
A blood marker that rises with inflammation.
Very low certaintyResults and what it means
Why it was measured
A simple check for body-wide inflammation.
Statistical vs. clinical meaning
Mixed and small; neither study shows cause.
Safety implication
None specific.
| Study | Result | People | Product |
|---|---|---|---|
| 7 | CRP and IL-6 higher with carrageenan in overweight participants | 20 young men | Carrageenan 250 mg twice a day for 2 weeks |
| 3 | Overall CRP ratio 1.07 (95% CI 0.74 to 1.55); poorer-health subgroup 1.91 (0.92 to 3.97) | 922 US adults using protein drinks | Carrageenan-containing liquid protein drinks versus powder drinks (survey) |
Other 3
Interleukin-6 and fecal calprotectin (gut inflammation markers)
Raised in the carrageenan group (IL-6); calprotectin trend in trials
IL-6 is an inflammation signal in the blood. Fecal calprotectin is a stool test that rises with gut inflammation.
Very low certaintyResults and what it means
Why it was measured
To see whether relapse in the colitis trial came with measurable inflammation.
Statistical vs. clinical meaning
A small signal in a tiny trial; the calprotectin change did not reach the usual p < 0.05 cut-off.
Safety implication
Relevant to people with ulcerative colitis; see Safety.
| Study | Result | People | Product |
|---|---|---|---|
| 1 | IL-6 rose in the carrageenan group (p = 0.02); fecal calprotectin rose with p = 0.06 (not significant); neither rose in the placebo group | 12 adults with ulcerative colitis in remission | Carrageenan capsules versus placebo, up to 1 year |
Insulin sensitivity
No overall change; lower in overweight participants in trials
How well the body responds to insulin to bring blood sugar down. Lower sensitivity (insulin resistance) is linked to type 2 diabetes.
Very low certaintyResults and what it means
Why it was measured
Animal studies suggested carrageenan could reduce it.
Statistical vs. clinical meaning
A subgroup signal in a small trial.
Safety implication
Relevant to people with prediabetes or diabetes; see Safety.
| Study | Result | People | Product |
|---|---|---|---|
| 7 | No significant overall difference; lower whole-body and liver insulin sensitivity in overweight participants (interaction p = 0.01 to 0.04) | 20 healthy young men (BMI average 24.5) | Carrageenan 250 mg twice a day for 2 weeks versus placebo |
Gut permeability (leaky gut markers)
Higher in the carrageenan period in trials
How easily substances pass through the gut lining, measured by a lactulose-mannitol test and blood zonulin.
Very low certaintyResults and what it means
Why it was measured
To test the idea that carrageenan inflames or loosens the gut lining.
Statistical vs. clinical meaning
A single small trial; no numbers in the abstract.
Safety implication
Unknown.
| Study | Result | People | Product |
|---|---|---|---|
| 7 | Carrageenan was associated with increased intestinal permeability (the abstract gives no numbers) | 20 healthy young men | Carrageenan 250 mg twice a day for 2 weeks versus placebo |
Safety
What studies and official sources say about side effects, medicines and who should check first. Each point shows what kind of evidence it comes from.
Main points to know 4
- Regulators accept food-grade carrageenan at current use, but the question is not closed. EFSA (2018) found no concern about cancer or genetic damage, but kept the acceptable daily intake as temporary because of gaps in the data. In its worst-case scenario for people who always buy the same brands, high intakes were up to about 10 times that temporary limit. EFSA said this may be overestimated but may be a safety concern. JECFA (FAO/WHO) lists the limit as 'not specified'. The US FDA allows it as a thickener, stabilizer or emulsifier. Authoritative guidance 9 11 10
- Do not mix up food carrageenan with poligeenan (degraded carrageenan). Poligeenan is a much smaller molecule made on purpose with strong acid and heat. EFSA says it has never been authorised as a food additive and is not used in food. Much of the animal work on gut damage and tumours used this form. IARC (1983, as quoted by EFSA) put carrageenan in group 3 (not classifiable) and degraded carrageenan in group 2B (possibly carcinogenic to humans) on rat evidence. Critics say the food additive can break down into the harmful form in the gut; reviewers linked to a carrageenan maker say it cannot. This is unresolved in people. Authoritative guidance 9 6 4 8 2
- People with ulcerative colitis or other inflammatory bowel disease: ask your gut doctor. In one very small trial (12 finishers), 3 people with ulcerative colitis given carrageenan capsules relapsed and none given placebo did. EFSA said this needs further investigation and that results suggesting carrageenan might make inflammatory bowel disease worse in people need clarification. It is a signal, not proof. Randomised trial very small 1 9
- Babies: EU and WHO advice differ. JECFA (2014) found carrageenan in infant formula up to 1000 mg per litre not of concern, for infants usually under medical supervision. EFSA (2018) did not adopt that view and repeated the earlier EU committee advice that it remains inadvisable in infant formula fed from birth, including formulas for special medical purposes. The EU limit for adults does not apply to babies under 12 weeks. Ask a paediatrician about formula. Authoritative guidance 9 11
Side effects 2
| Effect | How often | Severity and recovery | Evidence |
|---|---|---|---|
| Allergic reaction (rare). One case of anaphylaxis during a barium enema was linked to carrageenan by skin and blood tests. A rate is not known. Do not read this as a common reaction. | One case report from 1995. EFSA found no case reports of significant allergic or anaphylactic reactions after eating foods that contain carrageenan. | can be severe (anaphylaxis) in the one case reported Not described beyond that symptoms stopped on a carrageenan-free diet in that case. | Case report 5 9 |
| Higher gut permeability and, in overweight men, lower insulin sensitivity and higher CRP and IL-6, over 2 weeks of carrageenan capsules Capsules, not food. A small trial that needs repeating. | 20 healthy young men in one crossover trial; the overall insulin result was not significant and the overweight finding is a subgroup effect. | No symptoms reported in the abstract; lab changes only Not reported. | Randomised trial very small 7 |
Liver
No liver injury from carrageenan was found in the sources read. A liver-safety source (such as LiverTox) was not searched for carrageenan.
How often. No frequency was found.
Monitoring. No agency monitoring advice was found.
This is a safety connection. It is not evidence that Carrageenan supports liver health.
Medicines and supplements 1
| With | Why it matters | Importance | Evidence | What to do |
|---|---|---|---|---|
| Prescription and over-the-counter medicines prescription | No source read describes a medicine interaction with carrageenan. Diabetes medicines, colitis medicines and others were not specifically searched. | None found Not enough evidence | A pharmacist can check your own medicines, especially if you take medicine for diabetes or ulcerative colitis. |
Who should check first 6
| Situation | Advice | Evidence |
|---|---|---|
| Ulcerative colitis, Crohn's disease or other bowel inflammation | Ask your gut doctor whether to limit carrageenan. The evidence is one very small trial and animal work. | Randomised trial very small 1 9 |
| Babies, especially infant formula fed from birth | EFSA says it remains inadvisable in infant formula fed from birth; JECFA reached a different view for infants under medical supervision. Ask a paediatrician. | Authoritative guidance 9 11 |
| Known allergy to carrageenan | Avoid it and read labels (it may be listed as carrageenan or E407). Ask an allergist. For trouble breathing or swelling of the face or throat, call 911 or your local emergency number. | Case report 5 |
| Prediabetes, type 2 diabetes or overweight | Ask your doctor. One small trial saw lower insulin sensitivity in overweight men on carrageenan capsules; it needs repeating. | Randomised trial very small 7 |
| Pregnancy and breastfeeding | No human study or official pregnancy statement for carrageenan was read. EFSA reports animal studies where the highest dose tested caused no developmental harm in studies of sodium and calcium carrageenan. Ask your midwife or doctor about your own diet. | Animal and regulatory 9 |
| Young children and single-bite jelly sweets | EFSA (2004 opinion, quoted in 2018) said gel-forming additives, including carrageenan, in single-bite jelly mini-cups carry a choking risk. Their use in jelly mini-cups is not authorised in the EU. Keep gel sweets and jelly cups away from young children. | Authoritative guidance 9 |
Overdose, product quality and regulators
Summary. Food-grade carrageenan was well tolerated in animal studies reviewed by EFSA. The safety questions are the broken-down form, how much people actually eat, and gut inflammation in people.
Animal. EFSA: not absorbed intact. No harm at the highest doses tested in rats (3,400 to 3,900 mg per kg body weight per day for a subchronic study; up to 7,500 mg per kg per day in chronic studies). Degraded carrageenan caused colon lesions and ulceration in monkeys, and colitis then tumours in rats, per EFSA.
Human doses studied. Capsules of 250 mg twice a day for 2 weeks (insulin trial) and a lower amount than average dietary intake (colitis trial). No amount advice is given here.
High dose or long term signals. The EU acceptable daily intake is 75 mg per kg body weight per day and is called temporary. EFSA's refined worst-case estimate for people loyal to certain brands was up to about 10 times that at the 95th percentile.
Overdose response. Not found.
Genotoxicity. EFSA: carrageenan and processed Eucheuma seaweed did not raise a concern for genetic damage.
Quality is mainly about how small the carrageenan molecules are and what is left over from processing. Heavy metals and iodine in the source seaweed were not researched for this page.
Small-molecule fraction. EU rules limit the share of low-weight carrageenan (below 50 kDa), because it looks like the degraded form. One interested party told EFSA that material on the market does not always meet that limit. EFSA asked for a validated test method. 9
Bleach by-product in processed Eucheuma seaweed. EFSA notes that processed Eucheuma seaweed (E 407a) is sometimes bleached with calcium hypochlorite, which can raise a by-product called semicarbazide, and that industry has been trying other bleaching agents. EU rules also cap formaldehyde at 50 mg per kg of additive. 9
| Body | Action | Date |
|---|---|---|
| US FDA (21 CFR 172.620) (United States) | Carrageenan may be safely used in food as an emulsifier, stabilizer or thickener in the amount necessary. It is the refined hydrocolloid from named red seaweeds, a sulfated polysaccharide with 20 to 40 percent sulfate. source | 2026-10-01 |
| EFSA (European Union) | 2018 re-evaluation of carrageenan (E 407) and processed Eucheuma seaweed (E 407a): no concern for cancer or genetic damage; group acceptable daily intake of 75 mg per kg body weight per day made temporary; data to be improved within 5 years; inadvisable in infant formula fed from birth. source | 2018-04 |
| WHO and FAO JECFA (International) | 2014 (79th meeting): acceptable daily intake not specified; carrageenan in infant formula up to 1000 mg per litre not of concern. 2007 listing: inadvisable in infant formulas. source | 2014 |
| IARC (as quoted by EFSA) (International) | 1983: carrageenan group 3 (not classifiable); degraded carrageenan group 2B based on rat evidence, no human data. source | 1983 |
When to get medical help
- Trouble breathing, wheezing, swelling of the lips, face, tongue or throat, widespread hives or collapse after eating: possible anaphylaxis. Use epinephrine if prescribed, then call 911 or your local emergency number.
- Ulcerative colitis or Crohn's disease getting worse: blood in the stool, new severe diarrhoea or belly pain. Contact your gut doctor.
- A child choking on a jelly sweet or jelly cup: call 911 or your local emergency number.
Stop using the product and contact a clinician or emergency service. In the US, Poison Control is 1-800-222-1222.
General information only, not medical advice. Ask a clinician or pharmacist before use, especially with medicines, in pregnancy or with a health condition. See the Natural Remedy Safety guide.
Frequently asked questions
What is carrageenan?
Is carrageenan safe?
Is carrageenan the same as poligeenan?
Does carrageenan cause cancer?
No human study shows it. EFSA found no concern for cancer from food-grade carrageenan; IARC (1983, as quoted by EFSA) put it in group 3, not classifiable, and degraded carrageenan in group 2B on rat evidence. A 2001 review argued for caution; a 2002 review found no credible evidence of colon tumour promotion.
Does carrageenan make ulcerative colitis worse?
Does carrageenan affect blood sugar or insulin?
A 2-week trial in 20 healthy young men found no overall change in insulin sensitivity. In overweight men it was lower and CRP and IL-6 were higher. It is one small trial and needs repeating.
Is carrageenan okay in infant formula?
Is carrageenan allergenic?
Is carrageenan the same as sea moss?
Is carrageenan safe in pregnancy?
No human study or official pregnancy statement for carrageenan was found. EFSA reports animal studies of sodium and calcium carrageenan with no developmental harm at the highest dose tested. Ask your midwife or doctor.
What does it mean that the EU limit is temporary?
EFSA kept the group limit of 75 mg per kg body weight per day but called it temporary because of gaps in the chemistry, intake and biology data, and asked for better data within 5 years of its 2018 opinion. It is a request for more evidence, not a finding of harm.
Explore by health goal
Gut HealthDigestive SupportBlood Sugar BalanceInflammation BalancePreventive Wellness
Editorial transparency
- Written by
- AlternativeMed editorial team. Research compiled with AI assistance, then checked against the sources listed.
- Medical review
- None. This page has not been reviewed by a physician or pharmacist.
- First published
- 2026-10-26
- Last substantive update
- 2026-10-26
- How we research
- We started from our existing carrageenan summary, read the EFSA 2018 opinion, the JECFA database page and the US regulation text, and re-read PubMed abstracts for the trials, reviews and a case report. Only abstracts were read for studies. Items we could not verify are flagged in the research gaps.
- How we rate evidence
- See "How we rate evidence" in the Evidence tab.
- Independence
- No product is promoted on this page. No affiliate links are shown. Two cited reviews are by consultants linked to a carrageenan maker and the 2001 review and the colitis trial include an author who has argued against carrageenan; this is stated where they are used.
Sources 11
Each source was opened and checked. Where we read only the abstract, it says so. The small numbers in the text point here.
- Bhattacharyya S, Shumard T, Xie H, Dodda A, et al.. A randomized trial of the effects of the no-carrageenan diet on ulcerative colitis disease activity.. Nutr Healthy Aging. 2017. PMID 28447072. DOI 10.3233/NHA-170023. (abstract)
- Cohen SM, Ito N. A critical review of the toxicological effects of carrageenan and processed eucheuma seaweed on the gastrointestinal tract.. Crit Rev Toxicol. 2002. PMID 12389870. DOI 10.1080/20024091064282. (abstract)
- Lam CS, O'Connell K, Monroy-Iglesias MJ, Du M, et al.. Evaluation of the Association Between Carrageenan and Systemic Inflammation: Results From the National Health and Nutrition Examination Survey.. Mol Nutr Food Res. 2026. PMID 42117307. DOI 10.1002/mnfr.70484. (abstract)
- McKim JM, Willoughby JA Sr, Blakemore WR, Weiner ML. Clarifying the confusion between poligeenan, degraded carrageenan, and carrageenan: A review of the chemistry, nomenclature, and in vivo toxicology by the oral route.. Crit Rev Food Sci Nutr. 2019. PMID 29902080. DOI 10.1080/10408398.2018.1481822. (abstract)
- Tarlo SM, Dolovich J, Listgarten C. Anaphylaxis to carrageenan: a pseudo-latex allergy.. J Allergy Clin Immunol. 1995. PMID 7751512. DOI 10.1016/s0091-6749(95)70091-9. (abstract)
- Tobacman JK. Review of harmful gastrointestinal effects of carrageenan in animal experiments.. Environ Health Perspect. 2001. PMID 11675262. DOI 10.1289/ehp.01109983. (abstract)
- Wagner R, Buettner J, Heni M, Fritsche L, et al.. Carrageenan and insulin resistance in humans: a randomised double-blind cross-over trial.. BMC Med. 2024. PMID 39593091. DOI 10.1186/s12916-024-03771-8. (abstract)
- Weiner ML, McKim JM, Blakemore WR. Addendum to Weiner, M.L. (2016) Parameters and Pitfalls to Consider in the Conduct of Food Additive Research, Carrageenan as a Case Study.. Food Chem Toxicol. 2017. PMID 28651808. DOI 10.1016/j.fct.2017.06.022. (abstract)
- . EFSA ANS Panel (2018). Re-evaluation of carrageenan (E 407) and processed Eucheuma seaweed (E 407a) as food additives. EFSA Journal 16(4):5238. . . (full-text)
- . US eCFR, 21 CFR 172.620 Carrageenan. . . (full-text)
- . WHO JECFA database: Carrageenan (INS 407). . . (full-text)
Where to buy
Check the label first. Whatever you buy, look for these:
- The iodine amount: seaweed can be very high in iodine, which matters for thyroid conditions
- Heavy metal testing information from the maker
- Origin and harvest area
- Organic or tested labeling
Talk to a pharmacist or doctor before you start any supplement, especially if you take medicines. See the Safety tab for interactions.
Support our free guides: as an Amazon Associate we earn from qualifying purchases. Full disclosure.